AU2021329909A1 - Compositions and methods for mood enhancement - Google Patents

Compositions and methods for mood enhancement Download PDF

Info

Publication number
AU2021329909A1
AU2021329909A1 AU2021329909A AU2021329909A AU2021329909A1 AU 2021329909 A1 AU2021329909 A1 AU 2021329909A1 AU 2021329909 A AU2021329909 A AU 2021329909A AU 2021329909 A AU2021329909 A AU 2021329909A AU 2021329909 A1 AU2021329909 A1 AU 2021329909A1
Authority
AU
Australia
Prior art keywords
fatty acid
composition
pharmaceutically acceptable
acceptable salt
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021329909A
Other languages
English (en)
Inventor
Stephanie Venn-Watson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epitracker Inc
Original Assignee
Epitracker Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epitracker Inc filed Critical Epitracker Inc
Publication of AU2021329909A1 publication Critical patent/AU2021329909A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
  • Feed For Specific Animals (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2021329909A 2020-08-20 2021-08-18 Compositions and methods for mood enhancement Pending AU2021329909A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063068263P 2020-08-20 2020-08-20
US63/068,263 2020-08-20
PCT/US2021/046556 WO2022040346A1 (en) 2020-08-20 2021-08-18 Compositions and methods for mood enhancement

Publications (1)

Publication Number Publication Date
AU2021329909A1 true AU2021329909A1 (en) 2023-03-09

Family

ID=80323688

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021329909A Pending AU2021329909A1 (en) 2020-08-20 2021-08-18 Compositions and methods for mood enhancement

Country Status (6)

Country Link
US (1) US20230381127A1 (https=)
EP (1) EP4199751A4 (https=)
JP (1) JP7829552B2 (https=)
AU (1) AU2021329909A1 (https=)
CA (1) CA3189188A1 (https=)
WO (1) WO2022040346A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3908374A4 (en) 2019-01-09 2022-12-28 Epitracker, Inc. COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES
JP7404382B2 (ja) 2019-03-04 2023-12-25 エピトラッカー インコーポレイテッド 脂肪酸アナログ、ならびに認知機能障害、行動症状および慢性疼痛の処置におけるそれらの使用
EP4426130A1 (en) 2021-11-03 2024-09-11 Epitracker, Inc. Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2198661T3 (es) * 1998-01-21 2004-02-01 Fideline Composiciones que contienen feromonas para disminuir el estres, la ansiedad y la agresividad en los cerdos.
BR9917806B1 (pt) * 1998-01-21 2013-06-18 composiÇço de feromona para tratamento de estresse ou ansiedade em mamÍferos, e soluÇço.
FR2931676B1 (fr) * 2008-05-30 2011-01-14 Ceva Sante Animale Nouveaux modes d'administration d'un melange d'acides gras pour le traitement de mammiferes non humains
KR20120129898A (ko) * 2009-12-30 2012-11-28 베일러 리서치 인스티튜트 알츠하이머 질환 및 노화 뇌를 위한 보충대사 치료요법
US9295637B2 (en) * 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US10307388B2 (en) * 2016-12-29 2019-06-04 The United States Of America As Represented By The Secretary Of The Navy Compositions and methods for diagnosis and treatment of inflammation
AU2019274431B2 (en) * 2018-05-23 2025-03-13 Epitracker, Inc. Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity
KR102087634B1 (ko) * 2018-10-11 2020-03-11 (주)바이텍 항비만용 조성물

Also Published As

Publication number Publication date
CA3189188A1 (en) 2022-02-24
EP4199751A4 (en) 2024-09-04
EP4199751A1 (en) 2023-06-28
JP7829552B2 (ja) 2026-03-13
US20230381127A1 (en) 2023-11-30
JP2023538610A (ja) 2023-09-08
WO2022040346A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
US20230201153A1 (en) Compositions and methods for treatment of obesity
US20230381127A1 (en) Compositions and methods for mood enhancement
US20240016773A1 (en) Compositions and methods for diagnosis and treatment of conditions related to aging
RU2402326C1 (ru) Способ коррекции инсулинорезистентности при метаболическом синдроме
Endres et al. n‐3 polyunsaturated fatty acids: update 1995
US20060142390A1 (en) Treatment for severe melancholic depression
CN104902888A (zh) 施用包含二十二碳五烯酸的组合物的方法
WO2003051350A1 (en) Use of lipoxin analogs to promote cell defense against gram-negative infections
Duan et al. Oral glucosylceramide reduces 2, 4-dinitrofluorobenzene induced inflammatory response in mice by reducing TNF-alpha levels and leukocyte infiltration
CN101610765A (zh) 用于治疗炎症的新组合物
JP2005529903A (ja) 脳卒中等における二次的な脳疾患事象についてのエイコサペンタエン酸（ｅｐａ）およびドコサヘキサエン酸（ｄｈａ）の使用
Äikäs et al. Remodelling of plasma lipoproteins by icosapent ethyl-supplementation and its impact on cardiovascular disease risk markers in normolipidemic individuals
US20150159115A1 (en) Purification of dpa enriched oil
Gurunluoglu et al. Histopathological investigation of the effects of a combination of parenteral nutrition and hunger on rabbit splenic tissue
CN1942180A (zh) 必需脂肪酸在预防和/或治疗冠心病或动脉疾病患者的抑郁中的应用
Wright Diet-related Changes in Sensitivity to the Pharmacological Effects of Delta-9-tetrahydrocannabinol
Jawad et al. A study of cardio-protective properties of omega-3 fatty acids after occurrence of acute myocardial ischemia in patients admitted to Al-Hussein Hospital in Karbala